Want to see CH:TECN full AI Analyst Report?
Top Page
Tecan Group AG
(TECN)
Select Model
Select Model
Rating:59Neutral
Price Target:
CHF184.00
▲(33.33% Upside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by deteriorating financial performance in 2025 (margin compression and a swing to a net loss), partially offset by a still-solid balance sheet and positive cash generation. Technicals are supportive with strong trend momentum, but overbought readings raise near-term pullback risk. Valuation is a drag due to negative earnings despite a modest dividend yield.
Positive Factors
Conservative balance sheet
Low debt-to-equity provides durable financial flexibility to absorb earnings volatility and support capital allocation. This conservatism preserves capacity for targeted R&D, OEM investments or acquisitions, and cushions operations during revenue weakness, sustaining long-term strategic optionality.
Negative Factors
Multi-year revenue decline
Three consecutive years of top-line decline undermine scale economics and threaten the growth of the installed base that drives consumables and service revenue. Prolonged revenue contraction increases pressure on margins, reduces capacity to invest in product development, and raises execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low debt-to-equity provides durable financial flexibility to absorb earnings volatility and support capital allocation. This conservatism preserves capacity for targeted R&D, OEM investments or acquisitions, and cushions operations during revenue weakness, sustaining long-term strategic optionality.
Read all positive factors
Tecan Group AG (TECN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.35B
Dividend Yield2.31%
Average Volume (3M)44.12K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-5.54%
EPS Growth-264.90%
CountryCH
Employees3,074
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-8.74
Shares Outstanding12,825,883
10 Day Avg. Volume56,389
30 Day Avg. Volume44,118
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.41
Price to Sales (P/S)1.84
P/FCF Ratio15.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF180.25Price Target Upside30.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)6.06
Revenue Forecast (FY)CHF882.00M
Tecan Group AG Business Overview & Revenue Model
Company Description
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and b...
How the Company Makes Money
Tecan primarily makes money by selling laboratory automation instruments and associated recurring products and services to life science and diagnostics customers, and by supplying OEM solutions to other companies.
Key revenue streams typically in...
Tecan Group AG Earnings Call Summary
Earnings Call Date:Aug 12, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture. While Tecan reported strong order entry and growth in the Life Sciences business, challenges in China, a decline in the Partnering Business, and external factors such as tariffs and currency impacts posed significant challenges. The company's strategic initiatives in cost reduction and innovation are positive, but the current market environment remains difficult.Positive Updates
Revenue and EBITDA
Tecan delivered CHF 439.5 million in revenue for H1 2025, with an adjusted EBITDA of CHF 65.7 million and an adjusted EBITDA margin of 15%.
Negative Updates
Revenue Decline
Overall revenue for H1 2025 was down 5.9% in Swiss francs and 3.7% in local currencies, mainly due to lower sales volumes.
Read all updates
Q2-2025 Updates
Positive
Negative
Revenue and EBITDA
Tecan delivered CHF 439.5 million in revenue for H1 2025, with an adjusted EBITDA of CHF 65.7 million and an adjusted EBITDA margin of 15%.
Read all positive updates
Company Guidance
During the Tecan Half Year Results 2025 Conference Call, several key financial metrics and guidance for the remainder of the year were discussed. For the first half of 2025, Tecan reported revenue of CHF 439 million, with an adjusted EBITDA of CHF 65.7 million, yielding a margin of 15%. The order entry was CHF 458.3 million, with a book-to-bill ratio above 1, indicating a healthy demand pipeline. The Life Sciences segment returned to growth with sales of CHF 185.7 million, up 1.6% in local currencies, while the Partnering Business faced a 7.1% decline in local currencies. Tecan maintained its full-year guidance, anticipating sales to range from a low single-digit percentage decline to growth, with an adjusted EBITDA margin between 17.5% and 18.5%, contingent on currency and tariff impacts. The company also announced a share buyback program of up to CHF 120 million, reflecting confidence in its long-term growth prospects.Tecan Group AG Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
74
Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 882.48M | 934.28M | 1.07B | 1.14B | 946.62M |
| Gross Profit | 280.19M | 320.60M | 390.47M | 405.32M | 388.02M |
| EBITDA | 86.23M | 147.80M | 205.57M | 210.85M | 201.22M |
| Net Income | -110.65M | 67.66M | 132.07M | 121.13M | 121.66M |
Balance Sheet | |||||
| Total Assets | 1.70B | 2.12B | 2.07B | 2.16B | 2.04B |
| Cash, Cash Equivalents and Short-Term Investments | 311.37M | 406.01M | 366.42M | 293.24M | 241.91M |
| Total Debt | 218.32M | 321.35M | 316.09M | 307.68M | 313.66M |
| Total Liabilities | 546.60M | 686.15M | 725.06M | 776.40M | 800.26M |
| Stockholders Equity | 1.15B | 1.44B | 1.35B | 1.36B | 1.22B |
Cash Flow | |||||
| Free Cash Flow | 102.67M | 117.86M | 125.63M | 91.24M | 126.12M |
| Operating Cash Flow | 137.98M | 148.54M | 160.57M | 127.47M | 165.84M |
| Investing Cash Flow | 76.50M | -48.61M | -84.23M | -88.22M | -651.95M |
| Financing Cash Flow | -187.48M | -81.30M | -50.57M | -47.82M | 458.53M |
Tecan Group AG Technical Analysis
Positive
138.00
Price Trends
152.50
Positive
139.87
Positive
138.58
Positive
Market Momentum
8.04
Negative
69.30
Neutral
86.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:TECN, the sentiment is Positive. The current price of 138 is below the 20-day moving average (MA) of 164.88, below the 50-day MA of 152.50, and below the 200-day MA of 138.58, indicating a bullish trend. The MACD of 8.04 indicates Negative momentum. The RSI at 69.30 is Neutral, neither overbought nor oversold. The STOCH value of 86.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:TECN.
Tecan Group AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF5.00B | 22.56 | 27.15% | 0.67% | -2.39% | 154.37% | |
64 Neutral | CHF2.81B | 30.95 | 23.76% | 0.45% | 13.93% | 28.92% | |
62 Neutral | CHF3.29B | 18.97 | 15.79% | 0.51% | 2.57% | 4.31% | |
59 Neutral | CHF2.35B | -21.17 | 4.57% | 2.31% | -5.54% | -264.90% | |
57 Neutral | CHF1.34B | 79.31 | ― | 0.77% | -7.74% | -58.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | CHF1.23B | 134.18 | ― | ― | 19.76% | 150.73% |
* Healthcare Sector Average
CH:TECN
Tecan Group AG
185.00
28.34
18.09%
CH:MOVE
Medacta Group SA
137.60
1.65
1.21%
CH:SFZN
Siegfried Holding AG
73.05
-15.70
-17.69%
CH:YPSN
Ypsomed Holding AG
368.00
-42.92
-10.45%
CH:SKAN
SKAN Group AG
57.10
-15.16
-20.98%
CH:MED
Medartis Holding AG
89.90
10.50
13.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.